SlideShare uma empresa Scribd logo
1 de 20
MUSCLE HYPOTROPHY &
MUSCLE ATROPY
SARA MOHAMED RAFI
DEVIKA RESHMI BABU
AHAMMAD NAJAD SAYED
MAHIN MOHAMMED ADHIL
WHAT IS MUSCLE HYPOTROPHY?
Muscular hypotrophy refers to the decrease in muscle mass or size. It can
occur due to a variety of reasons such as disuse, malnutrition, aging
(sarcopenia), or certain diseases.
WHAT IS MUSCLE ATROPHY?
Muscular atrophy is the wasting or loss of muscle tissue.
It can occur due to various reasons, such as
1) prolonged inactivity,
2) aging,
3) malnutrition, or
4) specific diseases and conditions.
DIFFERENCE BETWEEN THE TWO
Increase in total mass of a muscle as hypertrophy, whereas a decrease in total mass of
a muscle is referred to as atrophy.
CLINICAL SYMPTOMS –
MUSCLE HYPERTROPHY
Muscular hypertrophy, particularly in the context of resistance training and
exercise, is generally considered a positive adaptation that leads to increased
muscle size and strength.
But extreme or abnormal cases of muscular hypertrophy, often unrelated to
exercise, can be associated with certain medical conditions.
• Hypertrophic Cardiomyopathy
• Benign Prostatic Hyperplasia (BPH)
• Muscular Dystrophy
• Acromegaly
• Pseudohypertrophy in Duchenne Muscular Dystrophy
CLINICAL SYMPTOMS – MUSCLE
ATROPHY
Muscle
Weakness
Reduced Muscle
Size
Physical
Disability
Muscle
Flaccidity
Decreased Mobility and
Function
Muscle Cramps and
Stiffness
Asymmetr
y
Fatigu
e
Unintentional Weight Loss
• Reversible Causes.
• Chronic or Progressive
Conditions
• Neurogenic Atrophy
• Age-Related Atrophy
(Sarcopenia)
• Individual Response to
Treatment.
• Early Intervention.
1. Medical History
2. Physical Examination
3. Neurological
Examination
4. Laboratory Tests
5. Imaging Studies
6. Electromyography (EMG)
7. Muscle Biopsy
8. Genetic Testing
9. Functional Assessments
10. Specialized Consultations
MANAGEMENT
• Regular Exercise
• Nutrition plan
• Surgery for contracture
• Ultrasound therapy
• Electrical Stimulation
• Balancing Hormone levels
• Avoiding Steroid Abuse
• Tumors or Masses
• Removal of Tumors or abnormal
• masses in muscles.
• Physical Therapy
• Medications
CASE STUDY-1
Background
Sarah, a 35-year-old woman, presented to her primary care physician with concerns about unexplained
muscle growth and weakness. She reported that over the past six months, she had noticed a significant
increase in the size of her limbs, particularly her arms and thighs. Despite the apparent muscular
hypertrophy, she experienced muscle weakness, fatigue, and occasional cramping.
Clinical Examination
• No significant history of intense physical training or resistance exercise.
• No family history of muscular disorders.
• Normal weight.
• No history of recent infections or significant changes in medication.
• Symmetrical muscular hypertrophy, particularly in the proximal muscle groups of the arms and thighs.
• Muscle strength testing revealed weakness, especially in the affected muscle groups.
• No signs of inflammation or joint abnormalities.
Diagnostic Workup
1. Blood Tests:
• Creatine kinase (CK) levels: Elevated.
2. Imaging:
• Magnetic Resonance Imaging (MRI) of affected muscle groups revealed hypertrophy without signs of
inflammation or structural abnormalities.
3. Genetic Testing:
• Screening for genetic mutations associated with muscular disorders (e.g., muscular dystrophies).
Diagnosis
After a comprehensive evaluation, Sarah was diagnosed with a rare form of muscular hypertrophy associated
with a genetic mutation leading to overexpression of growth-related factors in muscle cells. This condition
was causing muscle enlargement without a corresponding increase in strength, leading to weakness and
fatigue.
Treatment and Management
Since the condition was genetic, there was no cure, but management focused on improving Sarah's quality
of life.
Physical therapy was recommended to maintain mobility and prevent muscle contractures.
Regular monitoring of muscle function, CK levels, and overall health.
Conclusion
This case illustrates a rare scenario where muscular hypertrophy is not a result
of intentional exercise but is associated with an underlying genetic
CASE STUDY-11
Background
• Mark, a 45-year-old man, presented to his primary care physician with complaints of progressive weakness,
muscle wasting, and difficulty performing daily activities. He reported that over the past six months, he had
noticed a gradual reduction in the size and strength of his muscles, particularly in his arms and legs.
The symptoms had developed without any clear triggering events, such as trauma or prolonged
immobilization.
Clinical Examination
• No significant history of recent injuries or surgeries.
• No family history of neuromuscular disorders.
• Normal weight.
• No recent changes in medication or lifestyle.
• Muscle atrophy, especially noticeable in the distal muscle groups of the arms and legs.
• Muscle strength testing revealed generalized weakness, affecting both proximal and distal muscles.
• Reduced range of motion in affected joints.
• Normal sensation and reflexes.
Diagnostic Workup
1) Blood Tests:
• Creatine kinase (CK) levels: Within normal limits.
• Complete blood count (CBC), comprehensive metabolic panel (CMP): No significant abnormalities.
2) Neurological Testing:
• Electromyography (EMG) and nerve conduction studies to evaluate electrical activity in muscles and nerve
function.
• Magnetic Resonance Imaging (MRI) to rule out structural abnormalities.
3) Endocrine Testing:
• Thyroid function tests to rule out thyroid-related muscle disorders.
4) Autoimmune Markers:
• Screening for autoimmune disorders that may affect muscles.
Diagnosis
After a thorough evaluation, Mark was diagnosed with a neurological disorder affecting the motor neurons,
leading to progressive muscle atrophy. Further genetic testing revealed a mutation associated with a motor
neuron disease.
Follow-Up
• Mark continued to receive ongoing care and support from a multidisciplinary team, including neurologists,
physical therapists, and occupational therapists. Regular assessments were conducted to monitor his
muscle function, joint mobility, and overall well-being.
Conclusion
• This case illustrates a scenario where muscle atrophy is a result of an underlying neurological disorder with
a genetic basis. A comprehensive diagnostic approach, including neurological and genetic testing, is crucial
for accurate diagnosis and appropriate management. The focus is on providing supportive care to enhance
the patient's functional abilities and maintain their overall quality of life.
THANK YOU

Mais conteúdo relacionado

Semelhante a Muscle Hypertrophy.pptx

enzymes elevation cause muscle injury
enzymes elevation cause muscle injuryenzymes elevation cause muscle injury
enzymes elevation cause muscle injuryhira ali
 
Low back pain by Dr.bagasi
Low back pain by Dr.bagasi   Low back pain by Dr.bagasi
Low back pain by Dr.bagasi Abdulaziz Bagasi
 
Autologous Plasma and Regenerative Techniques (Prolotherapy, PRP, and Proloz...
Autologous Plasma and Regenerative Techniques (Prolotherapy, PRP,  and Proloz...Autologous Plasma and Regenerative Techniques (Prolotherapy, PRP,  and Proloz...
Autologous Plasma and Regenerative Techniques (Prolotherapy, PRP, and Proloz...Megan Hughes
 
Critical illness Polyneuropathy & Myopathy
Critical illness Polyneuropathy & MyopathyCritical illness Polyneuropathy & Myopathy
Critical illness Polyneuropathy & MyopathyNeurologyKota
 
Chronic Musculoskeletal Disorders and Physical Therapy Management
Chronic Musculoskeletal Disorders and Physical Therapy Management Chronic Musculoskeletal Disorders and Physical Therapy Management
Chronic Musculoskeletal Disorders and Physical Therapy Management Prochnost
 
myasthenia gravis.pptx
myasthenia gravis.pptxmyasthenia gravis.pptx
myasthenia gravis.pptxvaibhavpaul9
 
Physiotherapy in Myasthenia Gravis.pdf
Physiotherapy in Myasthenia Gravis.pdfPhysiotherapy in Myasthenia Gravis.pdf
Physiotherapy in Myasthenia Gravis.pdfHusneAraTarannumLask
 
EFFECT OF PHYSCIAL STRENGTH TRAINING IN SEDENTARY POPULATION.pptx
EFFECT OF PHYSCIAL STRENGTH TRAINING IN SEDENTARY POPULATION.pptxEFFECT OF PHYSCIAL STRENGTH TRAINING IN SEDENTARY POPULATION.pptx
EFFECT OF PHYSCIAL STRENGTH TRAINING IN SEDENTARY POPULATION.pptxTabassum Saher
 
Effects of Estrogen on Female Muscle and Tendon
Effects of Estrogen on Female Muscle and TendonEffects of Estrogen on Female Muscle and Tendon
Effects of Estrogen on Female Muscle and TendonLauren Jarmusz
 
Sarcopenia - identifying, measuring and managing muscle loss in elderly popul...
Sarcopenia - identifying, measuring and managing muscle loss in elderly popul...Sarcopenia - identifying, measuring and managing muscle loss in elderly popul...
Sarcopenia - identifying, measuring and managing muscle loss in elderly popul...Robert Ferris
 
HB1- science ver 9
HB1- science ver 9HB1- science ver 9
HB1- science ver 9Tony Chan
 
Motor system examination
Motor system examinationMotor system examination
Motor system examinationAhmed Koriesh
 
Muscle disorders
Muscle disordersMuscle disorders
Muscle disordersAnu Priya
 

Semelhante a Muscle Hypertrophy.pptx (20)

Ra conference may 2017
Ra conference may 2017Ra conference may 2017
Ra conference may 2017
 
enzymes elevation cause muscle injury
enzymes elevation cause muscle injuryenzymes elevation cause muscle injury
enzymes elevation cause muscle injury
 
Low back pain by Dr.bagasi
Low back pain by Dr.bagasi   Low back pain by Dr.bagasi
Low back pain by Dr.bagasi
 
Autologous Plasma and Regenerative Techniques (Prolotherapy, PRP, and Proloz...
Autologous Plasma and Regenerative Techniques (Prolotherapy, PRP,  and Proloz...Autologous Plasma and Regenerative Techniques (Prolotherapy, PRP,  and Proloz...
Autologous Plasma and Regenerative Techniques (Prolotherapy, PRP, and Proloz...
 
Critical illness Polyneuropathy & Myopathy
Critical illness Polyneuropathy & MyopathyCritical illness Polyneuropathy & Myopathy
Critical illness Polyneuropathy & Myopathy
 
Chronic Musculoskeletal Disorders and Physical Therapy Management
Chronic Musculoskeletal Disorders and Physical Therapy Management Chronic Musculoskeletal Disorders and Physical Therapy Management
Chronic Musculoskeletal Disorders and Physical Therapy Management
 
Ankylosing spondylitis
Ankylosing spondylitisAnkylosing spondylitis
Ankylosing spondylitis
 
physiotherapy in hormonal conditions
physiotherapy in hormonal conditionsphysiotherapy in hormonal conditions
physiotherapy in hormonal conditions
 
Osteoporosis
OsteoporosisOsteoporosis
Osteoporosis
 
myasthenia gravis.pptx
myasthenia gravis.pptxmyasthenia gravis.pptx
myasthenia gravis.pptx
 
Physiotherapy in Myasthenia Gravis.pdf
Physiotherapy in Myasthenia Gravis.pdfPhysiotherapy in Myasthenia Gravis.pdf
Physiotherapy in Myasthenia Gravis.pdf
 
EFFECT OF PHYSCIAL STRENGTH TRAINING IN SEDENTARY POPULATION.pptx
EFFECT OF PHYSCIAL STRENGTH TRAINING IN SEDENTARY POPULATION.pptxEFFECT OF PHYSCIAL STRENGTH TRAINING IN SEDENTARY POPULATION.pptx
EFFECT OF PHYSCIAL STRENGTH TRAINING IN SEDENTARY POPULATION.pptx
 
Effects of Estrogen on Female Muscle and Tendon
Effects of Estrogen on Female Muscle and TendonEffects of Estrogen on Female Muscle and Tendon
Effects of Estrogen on Female Muscle and Tendon
 
Spondylitis ppt.pptx
Spondylitis ppt.pptxSpondylitis ppt.pptx
Spondylitis ppt.pptx
 
Sarcopenia - identifying, measuring and managing muscle loss in elderly popul...
Sarcopenia - identifying, measuring and managing muscle loss in elderly popul...Sarcopenia - identifying, measuring and managing muscle loss in elderly popul...
Sarcopenia - identifying, measuring and managing muscle loss in elderly popul...
 
HB1- science ver 9
HB1- science ver 9HB1- science ver 9
HB1- science ver 9
 
Understanding Sarcopenia
Understanding SarcopeniaUnderstanding Sarcopenia
Understanding Sarcopenia
 
Motor system examination
Motor system examinationMotor system examination
Motor system examination
 
Mg 111309
Mg 111309Mg 111309
Mg 111309
 
Muscle disorders
Muscle disordersMuscle disorders
Muscle disorders
 

Último

Information science research with large language models: between science and ...
Information science research with large language models: between science and ...Information science research with large language models: between science and ...
Information science research with large language models: between science and ...Fabiano Dalpiaz
 
ANITINUTRITION FACTOR GYLCOSIDES SAPONINS CYANODENS
ANITINUTRITION FACTOR GYLCOSIDES SAPONINS CYANODENSANITINUTRITION FACTOR GYLCOSIDES SAPONINS CYANODENS
ANITINUTRITION FACTOR GYLCOSIDES SAPONINS CYANODENSDr. TATHAGAT KHOBRAGADE
 
PARENTAL CARE IN FISHES.pptx for 5th sem
PARENTAL CARE IN FISHES.pptx for 5th semPARENTAL CARE IN FISHES.pptx for 5th sem
PARENTAL CARE IN FISHES.pptx for 5th semborkhotudu123
 
An Overview of Active and Passive Targeting Strategies to Improve the Nano-Ca...
An Overview of Active and Passive Targeting Strategies to Improve the Nano-Ca...An Overview of Active and Passive Targeting Strategies to Improve the Nano-Ca...
An Overview of Active and Passive Targeting Strategies to Improve the Nano-Ca...NoorulainMehmood1
 
Introduction and significance of Symbiotic algae
Introduction and significance of  Symbiotic algaeIntroduction and significance of  Symbiotic algae
Introduction and significance of Symbiotic algaekushbuR
 
Polyethylene and its polymerization.pptx
Polyethylene and its polymerization.pptxPolyethylene and its polymerization.pptx
Polyethylene and its polymerization.pptxMuhammadRazzaq31
 
EU START PROJECT. START-Newsletter_Issue_4.pdf
EU START PROJECT. START-Newsletter_Issue_4.pdfEU START PROJECT. START-Newsletter_Issue_4.pdf
EU START PROJECT. START-Newsletter_Issue_4.pdfStart Project
 
Manganese‐RichSandstonesasanIndicatorofAncientOxic LakeWaterConditionsinGale...
Manganese‐RichSandstonesasanIndicatorofAncientOxic  LakeWaterConditionsinGale...Manganese‐RichSandstonesasanIndicatorofAncientOxic  LakeWaterConditionsinGale...
Manganese‐RichSandstonesasanIndicatorofAncientOxic LakeWaterConditionsinGale...Sérgio Sacani
 
NUMERICAL Proof Of TIme Electron Theory.
NUMERICAL Proof Of TIme Electron Theory.NUMERICAL Proof Of TIme Electron Theory.
NUMERICAL Proof Of TIme Electron Theory.syedmuneemqadri
 
A Scientific PowerPoint on Albert Einstein
A Scientific PowerPoint on Albert EinsteinA Scientific PowerPoint on Albert Einstein
A Scientific PowerPoint on Albert Einsteinxgamestudios8
 
Taphonomy and Quality of the Fossil Record
Taphonomy and Quality of the  Fossil RecordTaphonomy and Quality of the  Fossil Record
Taphonomy and Quality of the Fossil RecordSangram Sahoo
 
RACEMIzATION AND ISOMERISATION completed.pptx
RACEMIzATION AND ISOMERISATION completed.pptxRACEMIzATION AND ISOMERISATION completed.pptx
RACEMIzATION AND ISOMERISATION completed.pptxArunLakshmiMeenakshi
 
Classification of Kerogen, Perspective on palynofacies in depositional envi...
Classification of Kerogen,  Perspective on palynofacies in depositional  envi...Classification of Kerogen,  Perspective on palynofacies in depositional  envi...
Classification of Kerogen, Perspective on palynofacies in depositional envi...Sangram Sahoo
 
Warming the earth and the atmosphere.pptx
Warming the earth and the atmosphere.pptxWarming the earth and the atmosphere.pptx
Warming the earth and the atmosphere.pptxGlendelCaroz
 
GBSN - Microbiology (Unit 4) Concept of Asepsis
GBSN - Microbiology (Unit 4) Concept of AsepsisGBSN - Microbiology (Unit 4) Concept of Asepsis
GBSN - Microbiology (Unit 4) Concept of AsepsisAreesha Ahmad
 
Nanoparticles for the Treatment of Alzheimer’s Disease_102718.pptx
Nanoparticles for the Treatment of Alzheimer’s Disease_102718.pptxNanoparticles for the Treatment of Alzheimer’s Disease_102718.pptx
Nanoparticles for the Treatment of Alzheimer’s Disease_102718.pptxssusera4ec7b
 
Factor Causing low production and physiology of mamary Gland
Factor Causing low production and physiology of mamary GlandFactor Causing low production and physiology of mamary Gland
Factor Causing low production and physiology of mamary GlandRcvets
 

Último (20)

Chemistry Data Delivery from the US-EPA Center for Computational Toxicology a...
Chemistry Data Delivery from the US-EPA Center for Computational Toxicology a...Chemistry Data Delivery from the US-EPA Center for Computational Toxicology a...
Chemistry Data Delivery from the US-EPA Center for Computational Toxicology a...
 
Information science research with large language models: between science and ...
Information science research with large language models: between science and ...Information science research with large language models: between science and ...
Information science research with large language models: between science and ...
 
ANITINUTRITION FACTOR GYLCOSIDES SAPONINS CYANODENS
ANITINUTRITION FACTOR GYLCOSIDES SAPONINS CYANODENSANITINUTRITION FACTOR GYLCOSIDES SAPONINS CYANODENS
ANITINUTRITION FACTOR GYLCOSIDES SAPONINS CYANODENS
 
PARENTAL CARE IN FISHES.pptx for 5th sem
PARENTAL CARE IN FISHES.pptx for 5th semPARENTAL CARE IN FISHES.pptx for 5th sem
PARENTAL CARE IN FISHES.pptx for 5th sem
 
An Overview of Active and Passive Targeting Strategies to Improve the Nano-Ca...
An Overview of Active and Passive Targeting Strategies to Improve the Nano-Ca...An Overview of Active and Passive Targeting Strategies to Improve the Nano-Ca...
An Overview of Active and Passive Targeting Strategies to Improve the Nano-Ca...
 
Introduction and significance of Symbiotic algae
Introduction and significance of  Symbiotic algaeIntroduction and significance of  Symbiotic algae
Introduction and significance of Symbiotic algae
 
Polyethylene and its polymerization.pptx
Polyethylene and its polymerization.pptxPolyethylene and its polymerization.pptx
Polyethylene and its polymerization.pptx
 
EU START PROJECT. START-Newsletter_Issue_4.pdf
EU START PROJECT. START-Newsletter_Issue_4.pdfEU START PROJECT. START-Newsletter_Issue_4.pdf
EU START PROJECT. START-Newsletter_Issue_4.pdf
 
Manganese‐RichSandstonesasanIndicatorofAncientOxic LakeWaterConditionsinGale...
Manganese‐RichSandstonesasanIndicatorofAncientOxic  LakeWaterConditionsinGale...Manganese‐RichSandstonesasanIndicatorofAncientOxic  LakeWaterConditionsinGale...
Manganese‐RichSandstonesasanIndicatorofAncientOxic LakeWaterConditionsinGale...
 
NUMERICAL Proof Of TIme Electron Theory.
NUMERICAL Proof Of TIme Electron Theory.NUMERICAL Proof Of TIme Electron Theory.
NUMERICAL Proof Of TIme Electron Theory.
 
A Scientific PowerPoint on Albert Einstein
A Scientific PowerPoint on Albert EinsteinA Scientific PowerPoint on Albert Einstein
A Scientific PowerPoint on Albert Einstein
 
ABHISHEK ANTIBIOTICS PPT MICROBIOLOGY // USES OF ANTIOBIOTICS TYPES OF ANTIB...
ABHISHEK ANTIBIOTICS PPT MICROBIOLOGY  // USES OF ANTIOBIOTICS TYPES OF ANTIB...ABHISHEK ANTIBIOTICS PPT MICROBIOLOGY  // USES OF ANTIOBIOTICS TYPES OF ANTIB...
ABHISHEK ANTIBIOTICS PPT MICROBIOLOGY // USES OF ANTIOBIOTICS TYPES OF ANTIB...
 
Taphonomy and Quality of the Fossil Record
Taphonomy and Quality of the  Fossil RecordTaphonomy and Quality of the  Fossil Record
Taphonomy and Quality of the Fossil Record
 
RACEMIzATION AND ISOMERISATION completed.pptx
RACEMIzATION AND ISOMERISATION completed.pptxRACEMIzATION AND ISOMERISATION completed.pptx
RACEMIzATION AND ISOMERISATION completed.pptx
 
Classification of Kerogen, Perspective on palynofacies in depositional envi...
Classification of Kerogen,  Perspective on palynofacies in depositional  envi...Classification of Kerogen,  Perspective on palynofacies in depositional  envi...
Classification of Kerogen, Perspective on palynofacies in depositional envi...
 
Warming the earth and the atmosphere.pptx
Warming the earth and the atmosphere.pptxWarming the earth and the atmosphere.pptx
Warming the earth and the atmosphere.pptx
 
GBSN - Microbiology (Unit 4) Concept of Asepsis
GBSN - Microbiology (Unit 4) Concept of AsepsisGBSN - Microbiology (Unit 4) Concept of Asepsis
GBSN - Microbiology (Unit 4) Concept of Asepsis
 
Nanoparticles for the Treatment of Alzheimer’s Disease_102718.pptx
Nanoparticles for the Treatment of Alzheimer’s Disease_102718.pptxNanoparticles for the Treatment of Alzheimer’s Disease_102718.pptx
Nanoparticles for the Treatment of Alzheimer’s Disease_102718.pptx
 
Factor Causing low production and physiology of mamary Gland
Factor Causing low production and physiology of mamary GlandFactor Causing low production and physiology of mamary Gland
Factor Causing low production and physiology of mamary Gland
 
HIV AND INFULENZA VIRUS PPT HIV PPT INFULENZA VIRUS PPT
HIV AND INFULENZA VIRUS PPT HIV PPT  INFULENZA VIRUS PPTHIV AND INFULENZA VIRUS PPT HIV PPT  INFULENZA VIRUS PPT
HIV AND INFULENZA VIRUS PPT HIV PPT INFULENZA VIRUS PPT
 

Muscle Hypertrophy.pptx

  • 1. MUSCLE HYPOTROPHY & MUSCLE ATROPY SARA MOHAMED RAFI DEVIKA RESHMI BABU AHAMMAD NAJAD SAYED MAHIN MOHAMMED ADHIL
  • 2. WHAT IS MUSCLE HYPOTROPHY? Muscular hypotrophy refers to the decrease in muscle mass or size. It can occur due to a variety of reasons such as disuse, malnutrition, aging (sarcopenia), or certain diseases.
  • 3. WHAT IS MUSCLE ATROPHY? Muscular atrophy is the wasting or loss of muscle tissue. It can occur due to various reasons, such as 1) prolonged inactivity, 2) aging, 3) malnutrition, or 4) specific diseases and conditions.
  • 4. DIFFERENCE BETWEEN THE TWO Increase in total mass of a muscle as hypertrophy, whereas a decrease in total mass of a muscle is referred to as atrophy.
  • 5.
  • 6.
  • 7. CLINICAL SYMPTOMS – MUSCLE HYPERTROPHY Muscular hypertrophy, particularly in the context of resistance training and exercise, is generally considered a positive adaptation that leads to increased muscle size and strength. But extreme or abnormal cases of muscular hypertrophy, often unrelated to exercise, can be associated with certain medical conditions. • Hypertrophic Cardiomyopathy • Benign Prostatic Hyperplasia (BPH) • Muscular Dystrophy • Acromegaly • Pseudohypertrophy in Duchenne Muscular Dystrophy
  • 8. CLINICAL SYMPTOMS – MUSCLE ATROPHY Muscle Weakness Reduced Muscle Size Physical Disability Muscle Flaccidity Decreased Mobility and Function Muscle Cramps and Stiffness Asymmetr y Fatigu e Unintentional Weight Loss
  • 9. • Reversible Causes. • Chronic or Progressive Conditions • Neurogenic Atrophy • Age-Related Atrophy (Sarcopenia) • Individual Response to Treatment. • Early Intervention.
  • 10. 1. Medical History 2. Physical Examination 3. Neurological Examination 4. Laboratory Tests 5. Imaging Studies 6. Electromyography (EMG) 7. Muscle Biopsy 8. Genetic Testing 9. Functional Assessments 10. Specialized Consultations
  • 11. MANAGEMENT • Regular Exercise • Nutrition plan • Surgery for contracture • Ultrasound therapy • Electrical Stimulation • Balancing Hormone levels • Avoiding Steroid Abuse • Tumors or Masses • Removal of Tumors or abnormal • masses in muscles. • Physical Therapy • Medications
  • 13. Background Sarah, a 35-year-old woman, presented to her primary care physician with concerns about unexplained muscle growth and weakness. She reported that over the past six months, she had noticed a significant increase in the size of her limbs, particularly her arms and thighs. Despite the apparent muscular hypertrophy, she experienced muscle weakness, fatigue, and occasional cramping. Clinical Examination • No significant history of intense physical training or resistance exercise. • No family history of muscular disorders. • Normal weight. • No history of recent infections or significant changes in medication. • Symmetrical muscular hypertrophy, particularly in the proximal muscle groups of the arms and thighs. • Muscle strength testing revealed weakness, especially in the affected muscle groups. • No signs of inflammation or joint abnormalities.
  • 14. Diagnostic Workup 1. Blood Tests: • Creatine kinase (CK) levels: Elevated. 2. Imaging: • Magnetic Resonance Imaging (MRI) of affected muscle groups revealed hypertrophy without signs of inflammation or structural abnormalities. 3. Genetic Testing: • Screening for genetic mutations associated with muscular disorders (e.g., muscular dystrophies). Diagnosis After a comprehensive evaluation, Sarah was diagnosed with a rare form of muscular hypertrophy associated with a genetic mutation leading to overexpression of growth-related factors in muscle cells. This condition was causing muscle enlargement without a corresponding increase in strength, leading to weakness and fatigue. Treatment and Management Since the condition was genetic, there was no cure, but management focused on improving Sarah's quality of life. Physical therapy was recommended to maintain mobility and prevent muscle contractures. Regular monitoring of muscle function, CK levels, and overall health.
  • 15. Conclusion This case illustrates a rare scenario where muscular hypertrophy is not a result of intentional exercise but is associated with an underlying genetic
  • 17. Background • Mark, a 45-year-old man, presented to his primary care physician with complaints of progressive weakness, muscle wasting, and difficulty performing daily activities. He reported that over the past six months, he had noticed a gradual reduction in the size and strength of his muscles, particularly in his arms and legs. The symptoms had developed without any clear triggering events, such as trauma or prolonged immobilization. Clinical Examination • No significant history of recent injuries or surgeries. • No family history of neuromuscular disorders. • Normal weight. • No recent changes in medication or lifestyle. • Muscle atrophy, especially noticeable in the distal muscle groups of the arms and legs. • Muscle strength testing revealed generalized weakness, affecting both proximal and distal muscles. • Reduced range of motion in affected joints. • Normal sensation and reflexes.
  • 18. Diagnostic Workup 1) Blood Tests: • Creatine kinase (CK) levels: Within normal limits. • Complete blood count (CBC), comprehensive metabolic panel (CMP): No significant abnormalities. 2) Neurological Testing: • Electromyography (EMG) and nerve conduction studies to evaluate electrical activity in muscles and nerve function. • Magnetic Resonance Imaging (MRI) to rule out structural abnormalities. 3) Endocrine Testing: • Thyroid function tests to rule out thyroid-related muscle disorders. 4) Autoimmune Markers: • Screening for autoimmune disorders that may affect muscles. Diagnosis After a thorough evaluation, Mark was diagnosed with a neurological disorder affecting the motor neurons, leading to progressive muscle atrophy. Further genetic testing revealed a mutation associated with a motor neuron disease.
  • 19. Follow-Up • Mark continued to receive ongoing care and support from a multidisciplinary team, including neurologists, physical therapists, and occupational therapists. Regular assessments were conducted to monitor his muscle function, joint mobility, and overall well-being. Conclusion • This case illustrates a scenario where muscle atrophy is a result of an underlying neurological disorder with a genetic basis. A comprehensive diagnostic approach, including neurological and genetic testing, is crucial for accurate diagnosis and appropriate management. The focus is on providing supportive care to enhance the patient's functional abilities and maintain their overall quality of life.